In due time, the data will be given out the shareholders and public to be educated. However, it is the historically significant TLR of ANAVEX P2a/3 AD trial with all endpoints met that now guides the ANAVEX ship, and actions going forward. Developing A 2-73 for AD is the most financially impactful action that ANAVEX can take! It is number one. Everything else is a distant second.
No Pazzo, that is not the way it works. The company reads the safe harbor statement and then puts out its more-or-less ideal scenario. Only extremely naive people believe that no additional time or money will be needed. Most of us understand that it takes about twice as much time and money as initial projected and that underestimation is a fact of life as certain as death and taxes.
The company has now had two extremely successful P3 trials completed for two different indications: Rett and AD. This is extraordinary and despite the stock price not yet reacting, the CEO and everyone in the company is entitled to take a bow and receive a bonus.